7:00 PM
 | 
Feb 07, 2013
 |  BC Extra  |  Top Story

Amgen gives biosimilars guidance

At a business review on Thursday, Amgen Inc. (NASDAQ:AMGN) offered guidance on its six-product biosimilar portfolio, which the company said should have a first commercial launch in 2017 and generate up to $2 billion in peak revenues. The biotech did not disclose...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >